Logo

Danish Government Awards $1.6M to MicroRNA Research Consortium

May 01, 2006

NEW YORK, May 1 (GenomeWeb News) - Danish drug developer Santaris Pharma said today that it has created a MicroRNA Research Consortium in partnership with the Department for Medical Biochemistry and Genetics at the University of Copenhagen.

 

The new consortium is partially supported by a €1.3 million ($1.6 million) grant from the the Danish Advanced Technology Foundation. This will be matched by an additional €1.3 million from the University of Copenhagen and Santaris Pharma.

 

The consortium's first goal will be "to target microRNAs involved in human cancer and develop effective drugs that block their action," Santaris said.

 

The University will have the first right to patent new drug targets discovered in the partnership and Santaris will be responsible for the development and commercialization of antagonists of these targets as potential new cancer drugs.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.